Monitoring trajectories of emotion regulation over development could help flag at-risk children, authors say
WEDNESDAY, Nov. 27, 2024 (HealthDay News) — Trajectories of emotion regulation across ages 3 to 7 years predict attention-deficit/hyperactivity disorder (ADHD) symptoms, as well as conduct problems, according to a study recently published online in Development and Psychopathology.
Aja Louise Murray, Ph.D., from the University of Edinburgh in the United Kingdom, and colleagues used data from more than 19,000 children in the U.K.-based Millennium Cohort Study to evaluate whether developmental trajectories of emotion regulation across ages 3, 5, and 7 years predict levels of ADHD symptoms, internalizing problems, and conduct problems at age 7 years.
The researchers found that both higher initial levels of and slower reductions in emotion dysregulation across ages 3, 5, and 7 years predicted higher ADHD symptoms, conduct problems, and internalizing problems at age 7 years. Findings were seen in both male and female children.
“Emotion regulation skills are acquired from early in life and are thought to strengthen gradually over childhood. Children, however, acquire these skills at different rates and slower acquisition may serve as a marker for neurodevelopmental and mental health issues,” Murray said in a statement. “Our findings suggest that monitoring trajectories of emotion regulation over development could help identify which children are at risk of mental health issues.”
Maternal SARS-CoV-2 Infection Linked to Neurodevelopmental Diagnoses
Prenatal Exposure to Fine Particulate Matter Components Linked to Autism Spectrum Disorder Risk
Early Change in Family Structure May Increase Risk for Psoriasis
Type 2 Diabetes in Young Children Tied to Social, Environmental Factors
Local Greenness Linked to Lower Risk for Mental Health Hospital Admissions
Low and High Temperatures Linked to Mortality in the United States
AI Diabetes Prevention Program Yields Similar Results as Human-Led Program
GI Safety Profile Similar for Dulaglutide, Semaglutide, Tirzepatide